Home ›
Head and Neck Cancer Trials ›
NCT07254585
SYS6010 Combined With Enlonstobart In Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma
This study is an open-label, multi-center, phase II study to evaluate the efficacy and safety of SYS6010 combined with immunotherapy in the recurrent or metastatic head and neck squamous cell carcinoma.
Trial Details
NCT ID NCT07254585
Phase PHASE2
Sponsor CSPC Megalith Biopharmaceutical Co.,Ltd.
Status RECRUITING
Cancer Type Head and Neck Cancer
Interventions SYS6010 injection Enlonstobart injection Pembrolizumab injection
Locations (sample) Shanghai, Shanghai Municipality, China|31.22222,121.45806
Key Eligibility Criteria
Aged 18-75 (inclusive) years old, male or females; Participants with histologically confirmed recurrent or metastatic head and neck squamous cell carcinoma who are not suitable for radical surgery o… For SYS6010 combined with Enlonstobart group or SYS6010 combined with Pembrolizumab group : Participants who have not previously received systemic … For Enlonstobart group: Participants who have not previously received immunotherapy are included. For participants who have not previously undergon…
For full eligibility, visit ClinicalTrials.gov .